Healthcare of Ontario Pension Plan Trust Fund bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the first quarter, HoldingsChannel reports. The firm bought 4,664 shares of the company’s stock, valued at approximately $1,205,000.
Several other large investors have also recently modified their holdings of KRYS. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after buying an additional 481,200 shares during the period. Norges Bank bought a new stake in Krystal Biotech in the fourth quarter worth $70,159,000. William Blair Investment Management LLC boosted its stake in Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after buying an additional 227,038 shares during the period. Janus Henderson Group PLC boosted its stake in Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after buying an additional 209,369 shares during the period. Finally, UBS Group AG increased its position in Krystal Biotech by 970.8% during the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after acquiring an additional 177,922 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.
Insider Transactions at Krystal Biotech
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,642 shares of company stock valued at $8,243,923 in the last quarter. 13.10% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Read Our Latest Research Report on Krystal Biotech
Krystal Biotech Stock Down 7.0%
KRYS stock opened at $341.12 on Friday. Krystal Biotech, Inc. has a twelve month low of $130.50 and a twelve month high of $382.54. The firm has a market cap of $10.06 billion, a price-to-earnings ratio of 45.60 and a beta of 0.50. The business’s fifty day simple moving average is $339.70 and its two-hundred day simple moving average is $296.28.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. Research analysts expect that Krystal Biotech, Inc. will post 7.31 EPS for the current year.
Krystal Biotech Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
- Five stocks we like better than Krystal Biotech
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
